Interest in BCL-2 inhibition has increased, especially for patients with the t(11;14) translocation, a cytogenetic marker found in over 50% of individuals with AL amyloidosis and PCL, which is linked to and promotes BCL-2 activation (11, 12). This evidence concerns the gene BCL2 and plasma cell leukemia.